Several pharma companies think that targeting a rogue protein known as alpha-synuclein could be the key to halting or reversing neurodegeneration in Parkinson’s disease – but has the industry learned from a string of failures in Alzheimer’s? In the space of a few weeks, Novartis AG and Sanofi AS have signed major deals for molecules targeting misfolded alpha-synuclein, the rogue protein thought to be the root cause of Parkinson’s disease
Big pharma puts bets on alpha-synuclein i... - Cure Parkinson's
Big pharma puts bets on alpha-synuclein in Parkinson’s – but will they pay off?
Written by
Farooqji
To view profiles and participate in discussions please or .
Read more about...
2 Replies
•
Is there any evidence that alpha-synuclein is the culprit rather than an innocent side effect?
Not what you're looking for?
You may also like...
LL-37, a natural antimicrobial molecule present in the brain and gut, Suppresses Alpha-synuclein Clumping in Parkinson’s
alpha-synuclein protein — a hallmark of Parkinson’s disease — and prevents their further...
Phenylbutyrate for Alpha-synuclein Clearance from the Brain
prevent Parkinson’s disease (PD) in models that are genetically programmed to get the disease. The...
Do animal proteins cause an increase in alpha synuclein?
that indicated that animal proteins are one of the causes of alpha-synuclein, which is thought to...
Effect of Dietary Ketosis On Alpha-Synuclein Accumulation
cells in Parkinson's....
Allergy drug Montelukast (aka Singulair) reduced alpha synuclein load in mice genetically engineered to over produce alpha synuclein
Leukotriene Receptor Antagonist Montelukast Reduces Alpha-Synuclein Load and Restores Memory in an...